Olanzapine for the prevention of chemotherapy-induced nausea and vomiting

New England Journal of Medicine

Volumn 375, Issue 2, 2016, Pages 134-142

  Navari, Rudolph M ^a   Qin, Rui ^b   Ruddy, Kathryn J ^b   Liu, Heshan ^b   Powell, Steven F ^c   Bajaj, Madhuri ^d   Dietrich, Leah ^e   Biggs, David ^f   Lafky, Jacqueline M ^b   Loprinzi, Charles L ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d North Central Plains ^*  (United States)

^e GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^f CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FOSAPREPITANT; GRANISETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; PALONOSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; MORPHOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; CHEMICALLY INDUCED; COMPARATIVE STUDY; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; NAUSEA; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; VOMITING;

EID: 84978397859     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1515725     Document Type: Article

References (29)

1. Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 2015;20:576-83.
2. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 2013; 73: 249-62.
3. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 2015; 20: 450-8.
4. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014;25:1340-6.
5. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palo-nosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328-33.
6. Navari RM. Profile of netupitant/palo-nosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 2015; 9: 155-61.
7. Navari RM. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2015;15:1127-33.
8. Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2014; 722: 180-6.
9. Hocking CM, Kichenadasse G. Olan-zapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 2014; 22: 1143-51.
10. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-98.
11. Clinical practice guidelines in oncology, version 1: anti-emesis. Fort Washington, PA: National Comprehensive Cancer Network, 2015 (https://www.nccn.org/professionals/physician-gls/f-guidelines.a sp).
12. MASCC/ESMO antiemetic guidelines. Hillerød, Denmark: Multinational Association of Supportive Care in Cancer, 2013 (http://www.mascc.org/antiemetic-guide-l i nes).
13. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
14. 6 receptors by olanzapine. Eur J Pharmacol 2001;430:341-9.
15. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62: Suppl 7: 22-31.
16. Hale AS. Olanzapine. Br J Hosp Med 1997;58:442-5.
17. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomat ics 1999; 40: 438-43.
18. Navari RM, Gray SE, Kerr AC. Olan-zapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:188-95.
19. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009; 28: 131.
20. Mizukami N, Yamauchi M, Koike K, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2014;47:542-50.
21. Fonte C, Fatigoni S, Roila F. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol 2015;95:214-21.
22. Passik S, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004; 22: 383-8.
23. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005; 13:529-34.
24. Börjeson S, Hursti TJ, Peterson C, et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs 1997;20:260-6.
25. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton, FL: Chapman and Hall/CRC Press, 1999.
26. Abraha I, Montedori A. Modified intention to treat reporting in randomised controlled trials: systematic review. BMJ 2010;340:c2697.
27. 3 receptor antagonist from pivotal trials. Support Care Cancer 2014;22:Suppl:S107.
28. Schwartzberg L, Modiana M, Rapo-port B, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of moderately emetogenic chemotherapy or an-thracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 1071-8.
29. Rapoport B, Chasen M, Gridelli C, et al. Safety and efficacy assessment of ro-lapitant for the prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 2015;16:1079-89.